Novel ALS Therapeutic Target Identified from Motor Neuron Pathology: mGluR5

Discovery of mGluR5 dysfunction in ALS patients with TDP-43 pathology offers a new direction for the development of disease-modifying therapies

Circadian Rhythm Disorder, Migraine, Diabetes Drug

Small molecule compounds that selectively antagonist the photoreceptor molecule melanopsin (Opn4) expressed in retinal ganglion cells. They suppress non-visual light responses and can be used as drugs to improve diseases involving light responses and as research reagents for optogenetics.

Nutritional and Therapeutic Agents to Improve Neurodevelopment in Preterm Infants

Application of the Mechanism to Maintain Neural Stem Cells and Promote Neurogenesis through mTOR Signaling Regulation

Analgesic: A Novel Biased μ-Opioid Receptor Agonist

Selectively activating G-protein signaling to reduce side effects and enhance analgesic efficacy.

Rett Syndrome Therapeutic Drug

We have recently discovered that an already approved small-molecule therapeutic drug is effective against Rett syndrome. We propose the development of a new drug for Rett syndrome by repositioning the drug.

A Novel Therapeutic Drug for Niemann-Pick Disease Type C

Ceramide Kinase Inhibitor that Improves Intracellular Lipid Transport Disorders

Small molecule compounds that facilitate drug delivery to the brain

New deuterated flow synthesis system for drug development collaboration

Protein degrading small molecule drug for neurodegenerative disease

New chemical entities promoting degradation of ubiquitinated protein aggregates through induction of selective autophagy

NK1 receptor antagonist Development of a new treatment and prophylaxis for reflex syncope

Liver organoid model containing human hepatocytes for pharmacokinetic assay

Original method and hepatocyte reproduced hepatobiliary function